GSK and VIR Report EUA Submission to the US FDA for VIR-7831 to Treat COVID-19
Shots:
- The EUA submission is based on an interim analysis of the P-III COMET-ICE study assessing VIR-7831 vs PBO for the early treatment of COVID-19 in 583 adults at high risk of hospitalization
- The study demonstrated an 85% reduction in hospitalization. Due to evidence of profound efficacy- IDMC recommended stopping the trial for further enrollment
- Preclinical data of VIR-7831 suggested that the mAB maintains its activity against emerging variants. Additionally- the companies will continue discussions with the EMA and other global regulators to make VIR-7831 available to patients with COVID-19 asap
Ref: GSK | Image: GSK
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com